BerGenBio’s ‘ask the cell’ technology could potentially change cancer treatment as we know it. With an expanding patent portfolio and library of trade secrets behind it, what challenges does the startup biotech company face in bringing its first drugs to market?
LSIPR asked chief executive Richard Godfrey.
Cancer is the leading cause of death in Europe: a third of people living there will die from the disease. Improvements in treatments are making it easier to manage, and more people are surviving their cancers.
These days the majority of cancer fatalities are a result of cancer spread (metastasis) and metastatic tumours are often drug-resistant.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
BerGenBio, Richard Godfrey, cancer, CellSelect, IP strategy